6 avsnitt
The 411 on a GLP-1 Novo Nordisk
-
- Vetenskap
Join series hosts Dr. Jim Gavin, Clinical Professor of Medicine at Emory University and Chief Medical Officer at Healing Our Village, in Atlanta, GA; Dr. Aaron King, Family Medicine Physician with Baptist Health System Physicians, in San Antonio, TX; Dr. Jennifer Goldman, Professor of Pharmacy at Massachusetts College of Pharmacy, in Boston, MA, and Clinical Pharmacist at Well Life Medical, in Peabody, MA, and other fellow leaders in the field of diabetes as they tackle some of the challenges we face when treating T2D. Topics of discussion include the disease state of T2D, clinical inertia, the role of GLP-1 in glucose regulation, guidelines on early use of GLP-1 RAs in T2D treatment, as well as the mechanism of action, dosing and administration, efficacy and safety profiles, handling and storage, education of patients and pharmacists, and frequently asked questions regarding a once daily GLP-1 RA for adults with T2D.
This podcast series is sponsored by Novo Nordisk and is intended for clinicians.
-
Frequently Asked Questions About a GLP-1 RA Treatment Option for T2D
What do you need to know about a once daily GLP-1 RA therapy for adults with T2D? Join experts in T2D Aaron King, MD, Helen Baron, MD, and Stephen Brunton, MD, FAAP, FRACGP, CDCES, as they discuss frequently asked questions regarding the use of a once daily treatment for adults with T2D with the goal of helping to provide answers. Key topics include dosing and administration, handling and storage, as well as efficacy and safety.
-
Patient-Focused Care in T2D: The Pharmacist’s Role in GLP-1 RA Education
What is the role of the pharmacist in patient- centered care of adults with type 2 diabetes (T2D)? Join pharmacist experts in T2D Jennifer Goldman, RPh, PharmD, CDCES, BC-ADM, FCCP, Melody Hartzler, PharmD, BCACP, BC- ADM, AE-C, and Donald Nuzum, PharmD, BCACP, BC-ADM, CDCES, as they discuss education of patients and pharmacists on the pharmacokinetics, administration, dosing schedule and handling of a GLP-1 receptor agonist (GLP-1 RA). They will also consider when to use a GLP-1 RA, where they review clinical data on efficacy and safety of a GLP-1 RA, including in a trial when used as monotherapy vs placebo, a head-to-head study vs a DPP-4 inhibitor, and a cardiovascular outcomes study.
-
Explore A Treatment Option to Improve Glycemic Control in Adults With T2D
Explore a treatment option to improve glycemic control in adults with T2D and when you should consider using a GLP-1 RA. Join experts in T2D Aaron King, MD, Davida Kruger, MSN, APRN-BC, and Javier Morales, MD, as they review the disease state of T2D, the role of GLP-1 in glucose regulation, guidelines on early use of GLP-1 RAs in T2D treatment, as well as dosing, administration, and the monotherapy data of a once daily GLP-1 RA for T2D treatment.
-
What T2D Therapy Have You Considered for Your Patients After Metformin?
Join a multidisciplinary panel including Dr. Jim Gavin, Dr. Steve Vacalis, and Dr. Jodi Strong as they discuss and share their insights on the issues surrounding therapeutic inertia. They will also evaluate when to use a GLP-1 RA, and a clinical trial comparing the efficacy and safety of a GLP-1 RA versus a DPP-4i.
-
How to Empower Patients with T2D Knowledge and Introduce a GLP-1 RA
Join this multidisciplinary discussion with Jim Gavin, MD; Curtis Triplitt, PharmD; and Jeffrey Unger, MD, as they review the mechanism of action, dosing, efficacy, and safety of a once-daily GLP-1 RA for adult patients with T2D.
-
Could This GLP-1 RA be Right for Your Adult Patients With T2D?
Join leaders in the field of diabetes Dr. Jim Gavin, Dr. Pablo Mora, and Dr. Bob Busch as they navigate through a clinical study. What do you need to know about using a GLP-1 RA for glycemic control with patients who have T2D? Are there any considerations for specific populations such as those who have moderate renal impairment?